title: Esophagectomy for clinical high-grade dysplasia.
abstract: OBJECTIVE
  Esophageal high-grade dysplasia/tumor in situ (HGD/Tis) management is in evolution. However, treatment decisions must be made on clinical staging, which may not reflect pathologic staging. Long-term randomized trial information, large treatment series, and cancer registry data do not exist to guide treatment decisions. This evaluation of esophagectomy for clinically diagnosed HGD (cHGD) serves as a reference point for future therapies.
  
  
  METHODS
  From a 1296-patient prospective esophagectomy database, 134 patients were diagnosed with cHGD (HGD without detectable mass at biopsy) before esophagectomy (mean age 60 ± 10 years, 120 [90%] male, and 132 [99%] Caucasian). Median follow-up was 7.1 years.
  
  
  RESULTS
  Histopathologic cell type was adenocarcinoma in 124 (93%) patients. Pathologic T (tumor) classification (pT) was 77 (57%) pHGD, 46 (34%) pT1a, eight (6%) pT1b, and one each (1%) indefinite for dysplasia, low-grade dysplasia, and pT2. Three (2%) had regional lymph node metastases (pT1N1M0). There was one hospital death (0.7%) and four deaths from recurrent cancer. Survival at 1 month, 6 months, and 5, 10, and 15 years was 99%, 97%, 96%, 94%, 82%, and 75%, respectively. Survival was at least that of a matched population. Older age and poor lung function predicted worse survival. Sixteen patients developed nonesophageal cancers, 6.1 times greater than expected.
  
  
  CONCLUSIONS
  Despite clinical staging errors, survival following esophagectomy for cHGD is excellent. The diagnosis of cHGD does not alter survival referenced to the matched general population; however, cHGD patients appear to be at increased risk of second nonesophageal primary cancers. Therapy for cHGD should be patient specific, because patient and not cancer characteristics determine survival.
authors.affiliation: Department of Thoracic and Cardiovascular Surgery, Heart and Vascular Institute, Cleveland Clinic, Cleveland, OH 44195, USA. ricet@ccf.org
authors.forename: Thomas W
authors.initials: TW
authors.lastname: Rice
authors.forename: Sudish C
authors.initials: SC
authors.lastname: Murthy
authors.forename: David P
authors.initials: DP
authors.lastname: Mason
authors.forename: Lisa A
authors.initials: LA
authors.lastname: Rybicki
authors.forename: Lisa M
authors.initials: LM
authors.lastname: Yerian
authors.forename: John A
authors.initials: JA
authors.lastname: Dumot
authors.forename: Cristina P
authors.initials: CP
authors.lastname: Rodriguez
authors.forename: Eugene H
authors.initials: EH
authors.lastname: Blackstone
mesh_terms: D000328:Adult; D000367:Age Factors; D000368:Aged; D001471:Barrett Esophagus / Q000175:diagnosis / Q000473:pathology / Q000601:surgery*; D004812:Epidemiologic Methods; D004938:Esophageal Neoplasms / Q000175:diagnosis / Q000473:pathology / Q000601:surgery*; D016629:Esophagectomy / Q000009:adverse effects / Q000379:methods*; D005260:Female; D006801:Humans; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D060787:Neoplasm Grading; D009364:Neoplasm Recurrence, Local; D016609:Neoplasms, Second Primary; D011230:Precancerous Conditions / Q000175:diagnosis / Q000473:pathology / Q000601:surgery*; D016896:Treatment Outcome